KR102383824B1 - 암 치료법을 위한 메트로놈 경구 젬시타빈 - Google Patents

암 치료법을 위한 메트로놈 경구 젬시타빈 Download PDF

Info

Publication number
KR102383824B1
KR102383824B1 KR1020187038225A KR20187038225A KR102383824B1 KR 102383824 B1 KR102383824 B1 KR 102383824B1 KR 1020187038225 A KR1020187038225 A KR 1020187038225A KR 20187038225 A KR20187038225 A KR 20187038225A KR 102383824 B1 KR102383824 B1 KR 102383824B1
Authority
KR
South Korea
Prior art keywords
gem
delete delete
formulation
oral
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187038225A
Other languages
English (en)
Korean (ko)
Other versions
KR20190015420A (ko
Inventor
웨이-후아 하오
수-핑 슈에
창-샨 수
Original Assignee
이노파막스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노파막스, 인크. filed Critical 이노파막스, 인크.
Publication of KR20190015420A publication Critical patent/KR20190015420A/ko
Application granted granted Critical
Publication of KR102383824B1 publication Critical patent/KR102383824B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020187038225A 2016-06-02 2017-06-02 암 치료법을 위한 메트로놈 경구 젬시타빈 Active KR102383824B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344660P 2016-06-02 2016-06-02
US62/344,660 2016-06-02
PCT/CN2017/086942 WO2017206940A1 (en) 2016-06-02 2017-06-02 Metronomic oral gemcitabine for cancer therapy

Publications (2)

Publication Number Publication Date
KR20190015420A KR20190015420A (ko) 2019-02-13
KR102383824B1 true KR102383824B1 (ko) 2022-04-06

Family

ID=60479058

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187038225A Active KR102383824B1 (ko) 2016-06-02 2017-06-02 암 치료법을 위한 메트로놈 경구 젬시타빈

Country Status (10)

Country Link
US (1) US10835548B2 (https=)
EP (1) EP3463298B1 (https=)
JP (2) JP2019517490A (https=)
KR (1) KR102383824B1 (https=)
CN (2) CN114224865A (https=)
AU (1) AU2017273495B2 (https=)
CA (1) CA3026144A1 (https=)
ES (1) ES2898024T3 (https=)
TW (1) TWI814703B (https=)
WO (1) WO2017206940A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020247912A1 (en) * 2019-06-06 2020-12-10 Board Of Regents, The University Of Texas System Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
CN120478381A (zh) * 2025-07-02 2025-08-15 华中科技大学同济医学院附属同济医院 Azd1152和吉西他滨在制备治疗胆管癌药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
HUE047352T2 (hu) 2008-09-23 2020-04-28 Nektar Therapeutics Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)
WO2010039039A1 (en) * 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN101926779A (zh) * 2010-08-19 2010-12-29 苏州特瑞药业有限公司 一种吉西他滨固体脂质纳米粒及其制备方法与用途
KR20140079831A (ko) * 2011-10-18 2014-06-27 아지노모토 가부시키가이샤 췌장암 및／또는 담도암 치료약
WO2015153820A1 (en) * 2014-04-02 2015-10-08 Felder Mitchell S Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer

Also Published As

Publication number Publication date
CN114224865A (zh) 2022-03-25
AU2017273495B2 (en) 2023-01-12
JP2019517490A (ja) 2019-06-24
KR20190015420A (ko) 2019-02-13
US20170348341A1 (en) 2017-12-07
WO2017206940A1 (en) 2017-12-07
AU2017273495A1 (en) 2018-12-20
EP3463298B1 (en) 2021-09-01
TW201808309A (zh) 2018-03-16
TWI814703B (zh) 2023-09-11
ES2898024T3 (es) 2022-03-03
EP3463298A4 (en) 2020-01-01
CA3026144A1 (en) 2017-12-07
US10835548B2 (en) 2020-11-17
CN109310631A (zh) 2019-02-05
EP3463298A1 (en) 2019-04-10
JP2022088622A (ja) 2022-06-14

Similar Documents

Publication Publication Date Title
Zhai et al. Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy
RU2532362C2 (ru) Самомикроэмульгирующаяся оральная фармацевтическая композиция, содержащая гидрофильное лекарственное средство, и способ ее приготовления
ES2283756T3 (es) Sistemas autoemulsionantes de administracion de farmaco para taxoides.
US20070104780A1 (en) Formulation comprising a drug of low water solubility and method of use thereof
TWI838700B (zh) 口服紫杉烷組合物及方法
JP2002509877A (ja) 抗癌組成物
ES2688817T3 (es) Formulación en cápsulas solubilizadas de [(1S)-1-{[(2S,4R)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1R,2S)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
JP2022088622A (ja) がん療法のためのメトロノミック経口ゲムシタビン
ES2551125T3 (es) Composición antifúngica
Doi et al. Combination therapy of metronomic S‐1 dosing with oxaliplatin‐containing polyethylene glycol‐coated liposome improves antitumor activity in a murine colorectal tumor model
JP6484393B2 (ja) デュタステリドを含有する医薬組成物及びそれを含むカプセル製剤
EA016619B1 (ru) Новые композиции на основе таксоидов
EP1648440B1 (en) Semi-solid formulations for the oral administration of taxoids
JP2022088622A5 (https=)
US20210361599A1 (en) Carmustine formulation
US20160317540A1 (en) Therapeutic Treatment
US8541465B2 (en) Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20250387378A1 (en) Methods and compositions for preventing skin toxicities caused by biological targeted cancer drugs
HK1256760B (en) Oral taxane compositions and methods
NZ616410B2 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5